Summit Therapeutics plc (SMMT) News
Summit Therapeutics plc (SMMT)
Today's Latest Price: $3.27 USD
Updated Oct 30 4:00pm
Add SMMT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter SMMT News Items
SMMT News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SMMT News From Around the Web
Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.
Summit Therapeutics +3.8% as Zanganeh reports 7.8% stakeSummit Therapeutics (SMMT) is up 3.8% after-hours after an SEC filing shows a 7.8% stake taken by Maky Zanganeh. That comes via Zanganeh, her revocable trust, and the irrevocable trust of Shaun Zanganeh. The aggregate amount of shares beneficially owned amounts to 5.330,258. (Each trust holds about 2.104M shares, and... |
Summit Therapeutics +3.8% as Zanganeh reports 7.8?% stakeSummit Therapeutics (SMMT) is up 3.8% after hours after an SEC filing shows a 7.8% stake taken by Maky Zanganeh. That comes via Zanganeh, her revocable trust, and the irrevocable trust of Shaun Zanganeh. The aggregate amount of shares beneficially owned amounts to 5.330,258. (Each trust holds about 2.104M shares,... |
Summit Announces Intention to Redomicile its Holding Company to the United StatesSummit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA,. |
Summit Therapeutics announces publication of ridinilazole dataThinly traded micro cap Summit Therapeutics ([[SMMT]] +0.5%) is in the green, albeit trailing the broad market and on turnover of only 9.3K shares, on the heels of the publication of data from a Phase 2 clinical trial, CoDIFy, (that ended in October 2015) comparing small molecule antibiotic ridinilazole to vancomycin... |
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome HealthSummit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge,. |
Summit appoints Michael Donaldson as CFOSummit Therapeutics (SMMT) has appointed Mr. Michael Donaldson as Chief Financial Officer, effective immediately. Mr. Donaldson joins Summit from Goldfinch Bio, Inc., where he served as Vice President, Finance, and Corporate Controller.... |
Summit Appoints Michael Donaldson as Chief Financial OfficerSummit Therapeutics plc (SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corporate finance. “Michael joins us at an exciting time in Summit’s growth with our ongoing Phase 3 clinical trials of our precision antibiotic candidate, ridinilazole, and the potential to bring a superior product to patients with C. difficile infection,” said Mr. Bob Duggan, Executive Chairman and Chief Executive Officer of Summit. |
Is Summit Therapeutics PLC (SMMT) A Good Stock To Buy?Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […] |
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months. |
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?Is (SMMT) Outperforming Other Medical Stocks This Year? |
